person
Björn C.
- Country
- Germany
- Department
- Campus BenjaminFranklin Medizinische Klinik mit Schwerpunkt Hämatologie Onkologie Tumorimmunologie
Research Overview
assignment
14
Clinical Trials ·
- Phase II Study of Glofitamab-Based Induction Followed by CAR‑T Cell Therapy in High‑Risk Relapsed/Refractory Large B‑Cell Lymphoma
- Phase 3 Randomized Open‑Label Study of KITE‑753 Versus Axicabtagene Ciloleucel in Relapsed or Refractory Large B‑Cell Lymphoma After First‑Line Therapy
- Pilot-trial of methotrexate, tafasitamab (Minjuvi®), lenalidomide (Revlimid®) and rituximab in patients ineligible for HCT-ASCT with primary central nervous system lymphoma (PCNSL) -MTR²
location_city
2
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
103
Sites with multiple studies
Has run more than one trial at 103 of 225 partner sites.
Specializations
Lymphoma Research Focus
Specializes in investigating innovative treatments for B-cell lymphomas, with particular emphasis on diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma.
- First-line Treatment Strategies
- Aggressive B-cell Lymphomas
- Relapsed/Refractory Disease Management
Specialized Therapeutic Areas
Focuses on advanced therapeutic approaches including antibody-drug conjugates, bispecific antibodies, and novel combination therapies for lymphoid malignancies.
- Immunotherapy Applications
- T-cell Lymphoma Treatments
- Central Nervous System Lymphoma
Treatment Innovation
Investigates emerging therapeutic modalities including BTK inhibitors, PD-1 inhibitors, and targeted approaches for specific lymphoma subtypes.
- Novel Drug Combinations
- Chemotherapy-Light Regimens
- Maintenance Therapy Strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.